Rosetta Genomics Ltd. (USA) (NASDAQ:ROSG)

CAPS Rating: 2 out of 5

The Company is seeking to develop and commercialize new diagnostic and therapeutic products based on a recently discovered group of genes known as microRNAs.

Results 1 - 3 of 3

Recs

0
Member Avatar 2gud2btrue (81.63) Submitted: 5/1/2014 10:28:02 AM : Outperform Start Price: $3.81 ROSG Score: -7.37

Target $10

Recs

3
Member Avatar zzlangerhans (99.76) Submitted: 1/31/2014 9:23:45 PM : Underperform Start Price: $3.58 ROSG Score: +6.88

I guessed wrongly that Rosetta would continue to be volatile in 2013, and paid for it with a fat negative score on my green thumb. I recently revisited the stub and didn't find much to get excited about. The company only reports revenues every six months so there was no data in November, which to me just means more of a fall when dismal Cancer Origin test revenues are reported in March. In August the company provided the usual boilerplate excuses for their dismal six month revenues of 193K and swore they were improving the reimbursement rates for the test. I don't believe them.

Recs

1
Member Avatar vanguardtrader (71.52) Submitted: 6/18/2012 2:43:50 AM : Outperform Start Price: $9.70 ROSG Score: -110.59

This is the best speculative opportunity I have ever seen since I have started investing in stocks 7 years ago. Rosetta Genomics had been knocked down close to insolvency because it couldn't sell its technology. For starters its technology was way ahead of its time and is now coming into the lime-light as targeted cancer theraputics are the next revolution of the battle against cancer. Rosetta genomics can help pin-point an early detection or probability of certain types of cancers and owns 40% of the intellectual property rights in the genomics space. Rosetta Genomics deals with micro Rna's and has recently been approved by Medicare to cover its Mets2 testing. This will expose the test to 45 million medicare participants and 200k patients in direct need of the CUP (cancer of unkown primary test). Rosetta Genomics is in the right space at the right time as Genomics is heating up across the board. ROSG has also recently raised enough money to avoid bankruptcy and to buy time to build its new business model. ROSG at $10/share is sporting a 24m market cap. Most of Rosetta's peers are at least double in size. Based on Rosetta's intellectual property rights and its new approval I'm guessing it will be a 10 bagger in 5 years.

Results 1 - 3 of 3

Featured Broker Partners


Advertisement